The reimbursement landscape for medical device companies has fundamentally shifted. If you’re leading market access or health economics at a MedTech firm, you’ve already noticed that payers aren’t satisfied with clinical trial data anymore. They want proof that your device works in the messy reality of everyday clinical practice — across diverse patient populations, in various care settings, with real-world economic impact.
Here’s the uncomfortable truth: your randomized controlled trial might show stunning efficacy in 500 carefully selected patients, but payers are asking, “What happens when 50,000 beneficiaries with multiple comorbidities use this device?” That’s where real-world data and claims analytics become essential rather than optional.
Why Traditional Evidence Falls Short in Today’s Reimbursement Environment
Medical device market access teams face a fundamental mismatch between the evidence they generate and what payers actually demand. Clinical trials — the gold standard for regulatory approval — typically involve highly selected patient populations, controlled environments, and relatively short follow-up periods. Payers, on the other hand, operate in a world where patients have multiple chronic conditions, physicians vary in their expertise, and long-term outcomes determine total cost of care.
The FDA has recognized this gap. Their 2023 guidance on real-world evidence for medical devices explicitly acknowledges that RCTs alone cannot answer all relevant clinical questions, particularly for breakthrough devices or those used in complex, heterogeneous populations. The European Medicines Agency has similarly emphasized the critical role of real-world evidence in their vision for EU medicines regulation.
But acknowledging the need for real-world evidence and actually generating it are two different challenges entirely.
The Evidence Gaps That Kill Reimbursement Approvals
When MedTech companies submit reimbursement dossiers without adequate real-world evidence, specific gaps emerge repeatedly. Payers want to understand actual utilization patterns — which physicians are using the device, how frequently, and in what clinical contexts. They need cost-effectiveness models that reflect real-world pricing, not list prices that nobody actually pays. And they absolutely require evidence of comparative effectiveness against existing treatment alternatives… not just against placebo or standard of care from five years ago.
These aren’t academic concerns. A delayed reimbursement decision costs a typical MedTech company millions in lost revenue every quarter. Some innovative devices never achieve broad coverage because companies couldn’t demonstrate value in real-world settings. The stakes are genuinely high.
How Aggregated Claims Data Transforms MedTech Market Access Strategy
Claims data represents the most comprehensive record of healthcare utilization that exists. Every diagnosis, procedure, prescription, and healthcare encounter generates a claim when an insurer pays for services. For MedTech market access professionals, this creates unprecedented visibility into the real-world landscape where your device will compete.
Think about what’s actually captured in aggregated claims datasets. You can identify patient cohorts based on diagnosis codes, track their complete treatment journey across multiple providers, observe procedure volumes by geography and facility type, and analyze economic outcomes including hospitalization rates, complication costs, and total cost of care. This isn’t theoretical — it’s what actually happened to real patients.
The Power of Privacy-Compliant Aggregated Datasets
One persistent challenge with claims data has been privacy compliance. Traditional approaches required companies to navigate complex data use agreements, face restrictions on individual-level data access, and worry constantly about GDPR and HIPAA compliance. The FDA’s recent updates to their real-world evidence program in 2025 have eased some requirements around deidentified data, but concerns remain.
This is where aggregated and synthetic claims datasets become transformative. Aggregated data provides population-level insights without exposing individual patient information. You can analyze treatment patterns, outcomes, and costs across thousands or millions of patients while maintaining full GDPR compliance and privacy protection. For early market assessments and strategic planning, this often provides exactly the insights you need without the regulatory complexity of patient-level data access.
Synthetic data takes this further. Generated using advanced techniques like Generative Adversarial Networks (GANs), synthetic healthcare datasets maintain the statistical properties and relationships of real claims data while containing zero actual patient information. A comprehensive 2023 review in the Journal of Medical Internet Research demonstrated that synthetic health data can replicate real-world distributions and correlations with remarkable fidelity, making it suitable for scenario modeling, algorithm development, and preliminary analyses before investing in more expensive patient-level datasets.
Five Critical Applications of Real-World Data for MedTech Reimbursement
Let me walk through the specific ways that real-world and claims data solve actual market access challenges that MedTech companies face daily.
1. Building Credible Health Economic Models and Value Dossiers
Health Technology Assessment bodies like NICE in the UK have established rigorous frameworks for evaluating new medical technologies. Their 2022 real-world evidence framework explicitly outlines when and how real-world data should supplement clinical trial evidence in submissions.
Here’s what changes when you build economic models using real claims data rather than literature estimates and assumptions. First, your cost inputs reflect actual reimbursement rates and utilization patterns rather than list prices. Second, your baseline comparator costs come from observed treatment pathways in real patients, not idealized clinical scenarios. Third, your model can incorporate actual complication rates, readmission frequencies, and long-term outcome distributions observed in routine practice.
The difference in credibility is substantial. Payers trust models built on their own data far more than models relying on published literature that may not reflect current practice patterns or local cost structures. When you can demonstrate that your device reduces total cost of care by analyzing thousands of real procedures in claims data, that argument carries weight.
2. Generating Evidence for Coding, Coverage, and Payment Decisions
The “three-legged stool” of US medical device reimbursement — appropriate billing codes, coverage policies, and adequate payment levels — each requires different types of evidence. Claims data supports all three.
For coding, you need to demonstrate that existing CPT or HCPCS codes inadequately describe your device’s use, or that your device represents a significant modification requiring a new code. Claims analysis of analogous procedures provides the utilization data and cost benchmarks that coding authorities require.
Coverage policies demand evidence of medical necessity and clinical appropriateness. Real-world data showing improved outcomes, reduced complications, or shorter hospital stays in actual practice settings directly addresses payer concerns about whether the device should be covered at all.
Payment rate negotiations benefit enormously from claims analytics on procedure volumes, facility costs, physician time requirements, and comparison to existing reimbursement rates for similar procedures. You’re negotiating with data rather than opinions.
3. Mapping Patient Pathways and Identifying Market Opportunities
Understanding the diagnosis-to-treatment journey for your target patient population isn’t just an academic exercise — it directly impacts launch strategy, sales force deployment, and market forecasting. Claims data reveals these pathways at scale.
Consider a company launching an innovative cardiovascular device. Claims analysis can identify how many patients receive the current standard of care annually, what diagnostic tests precede treatment decisions, which specialists are involved in care coordination, where patients receive treatment (academic medical centers vs. community hospitals), and what happens to patients who don’t receive any intervention. This intelligence shapes everything from clinical education priorities to geographic expansion strategy.
You can also identify variations in care patterns by region, insurance type, or patient demographic characteristics. These variations often represent market opportunities where clinical practices haven’t yet adopted optimal treatment approaches — or where reimbursement barriers limit access despite clinical evidence.
4. Supporting HTA Submissions and Payer Negotiations
Health Technology Assessment processes vary significantly across markets, but they increasingly emphasize real-world evidence. European HTA bodies like France’s HAS, England’s NICE, and similar organizations across the continent expect companies to demonstrate not just efficacy in trials but effectiveness in routine practice.
Claims data addresses several specific HTA requirements that trial data cannot. You can demonstrate generalizability across broader patient populations, including elderly patients, those with multiple comorbidities, and underrepresented demographic groups typically excluded from trials. Long-term outcomes beyond typical trial follow-up periods become observable. Comparative effectiveness against multiple treatment alternatives (not just the single comparator in your pivotal trial) can be assessed.
For payer negotiations in markets without formal HTA processes, claims analytics provides the economic evidence that influences coverage decisions. When you can show a private payer that similar insurers cover your device and observe favorable outcomes and costs in their member populations, you’re making an evidence-based argument for coverage.
5. De-Risking Launch Strategy Through Early Market Intelligence
Perhaps the most underutilized application of real-world data is in pre-launch planning. Too many MedTech companies begin serious market access work only after regulatory approval, discovering too late that payer appetite doesn’t match their forecasts or that reimbursement barriers will delay commercial success.
Claims data enables early, evidence-based market assessment. You can size the patient population with precision rather than rough estimates. You can identify which competitors actually dominate treatment in real-world practice (not just the ones you’ve heard about). You can spot geographic markets where current treatment patterns suggest strong commercial opportunity. You can model the economic impact of your device using actual baseline costs and utilization patterns.
This intelligence should inform your entire clinical development strategy. If claims data reveals that the patients most likely to benefit from your device typically receive care in community hospitals rather than academic medical centers, your trial site selection and commercial strategy should reflect this reality. If real-world treatment patterns show that patients often fail multiple therapies before reaching your device’s target indication, your health economic model needs to capture this treatment sequencing.
Understanding Your Data Partnership Options
The challenge many MedTech companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities and specific use cases.
Key Dimensions of Claims Data Capabilities
The claims data landscape includes dozens of providers with overlapping but distinct offerings. Understanding the key dimensions of variation helps you evaluate options systematically:
Coverage breadth and depth: Some providers maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions, payer types, and care settings. Others focus on specific geographies, populations, or therapeutic areas with greater granularity. The optimal choice depends on whether you need breadth for market sizing or depth for understanding specific patient segments.
Data recency and update frequency: Providers vary in how quickly claims data becomes available for analysis. Some offer near-real-time access to adjudicated claims, enabling rapid market monitoring. Others work with older datasets that may lag current practice by 12-18 months. Your use cases determine which trade-offs make sense—forecasting demands recency, while retrospective outcomes studies can tolerate longer lags.
Analytical sophistication: Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. Some providers offer self-service tools for exploratory analysis, while others provide full-service analytics with dedicated teams. The choice depends on your internal capabilities and whether you need descriptive intelligence or forward-looking insights.
Data integration and enrichment: Some sources combine claims with complementary data—lab results, specialty pharmacy records, provider characteristics, social determinants of health. This vertical integration creates analytical possibilities that pure claims data cannot support, particularly for complex patient journey mapping and outcomes prediction.
Therapeutic area expertise: While most claims databases cover all therapeutic areas, some providers have developed specialized capabilities in specific disease states. This domain expertise can be valuable for complex analyses requiring deep clinical understanding, though it comes at premium pricing.
Cost Models and Licensing Structures
Pricing for claims data varies dramatically based on scope, access model, and analytical services. Understanding common cost structures helps you budget appropriately:
Some providers charge based on covered lives (annual fees per million patients in the dataset), others on data elements accessed, and still others on project scope. Self-service platform access typically costs less than full-service analytics, but requires internal expertise. Multi-year commitments often secure better pricing but limit flexibility as your needs evolve.
Navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem. The gap between understanding what claims data can do and identifying which specific provider configuration matches your needs is substantial.
Critical Considerations in Data Source Selection
Before evaluating specific providers, define your requirements across several dimensions:
Use Case Clarity
Different applications demand different data characteristics. Market sizing requires broad population coverage but may tolerate less granular detail. Patient journey mapping needs longitudinal tracking with complete episode visibility. Health economics modeling demands cost data accuracy and comprehensive comorbidity capture. Competitive intelligence benefits from real-time updates and market share tracking.
Most companies need multiple use cases supported simultaneously, which often means working with more than one data source or choosing providers with complementary strengths across your priority applications.
Geographic and Population Coverage
If your device targets specific markets, ensure data sources provide adequate representation. Continental European data may not generalize to US populations due to different treatment practices and healthcare system structures. Commercial insurance claims don’t capture Medicare populations, which may be your primary target for certain devices.
Understanding which payer types, geographies, and demographic segments appear in the data—and in what proportions—prevents costly mismatches between your analytical needs and data capabilities.
Internal Capabilities and Resource Constraints
Honestly assess your team’s analytical sophistication. Self-service platforms require epidemiological expertise, statistical programming skills, and substantial time investment. Full-service analytics costs more but delivers insights faster with less internal lift. Many companies start with full-service to build capabilities, then transition to hybrid or self-service models as expertise grows.
Budget constraints also shape viable options. Enterprise-scale data licensing can cost hundreds of thousands to millions annually. Project-based access to focused datasets may cost tens of thousands. Understanding total cost of ownership—including licensing, analytical services, and internal resources—helps evaluate true affordability.
Compliance and Privacy Requirements
GDPR compliance for European operations, HIPAA compliance for US data, and various international privacy regulations create complex requirements. Some providers specialize in navigating these regulatory frameworks, offering pre-cleared datasets and analysis approaches that meet compliance standards. Others require substantial legal review before use.
For companies operating across multiple markets, understanding how different data sources handle cross-border data transfer and privacy protection prevents compliance issues that could derail projects mid-stream.
Getting Started: A Strategic Approach
The path to effective claims data utilization involves several critical steps:
1. Define Requirements Before Evaluating Options
Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches and focuses evaluation on dimensions that actually matter for your use cases.
Expert consultants can help structure this requirements definition process, drawing on experience with dozens of similar engagements to ensure you’re considering factors that companies often overlook initially.
2. Understand the Landscape Dimensions
The claims data market evolves rapidly, with new providers emerging, existing players expanding capabilities, and pricing models shifting. What worked for your competitor two years ago may not represent the best current option. Understanding the full landscape—not just the most visible players—reveals opportunities for better fit at lower cost.
This is where expert guidance provides particular value. Advisors who work across the pharmaceutical industry and maintain current knowledge of the vendor landscape can identify providers you may not have considered while steering you away from options that seem attractive but carry hidden limitations.
3. Pilot Before Scaling
Start with a focused project to validate that your chosen approach answers your questions before committing to large-scale licensing agreements. A 3-6 month pilot addressing one high-priority use case reveals whether the data quality, analytical tools, and provider responsiveness meet your needs in practice, not just in sales presentations.
Pilots also build internal capabilities and stakeholder buy-in. When commercial teams see actionable insights from real-world data, they become champions for broader adoption. When finance sees concrete ROI, they support scaling investment.
4. Leverage Expert Guidance for Strategic Decisions
The gap between licensing claims data and extracting actionable intelligence is substantial. Many companies invest hundreds of thousands in data licensing only to struggle with actually generating insights that inform decisions. Understanding which combination of data sources, analytical capabilities, and domain expertise matches your specific needs requires deep market knowledge that most organizations lack internally.
Expert advisors who understand both your business objectives and the vendor landscape can accelerate your path to value while avoiding common pitfalls. They’ve seen what works and what fails across similar use cases, which providers deliver on promises and which oversell capabilities, and how to structure engagements that maximize ROI while minimizing risk.
This guidance becomes particularly valuable when navigating: vendor selection among dozens of seemingly similar options, pricing negotiations where you lack benchmarks, scope definition to ensure you’re purchasing what you actually need, analytical approach selection based on your team’s capabilities, and integration planning to connect claims insights with existing commercial intelligence.
Common Pitfalls in Claims Data Adoption
Understanding where others stumble helps you avoid expensive mistakes:
Choosing Based on Brand Recognition Rather Than Fit
The largest, most visible data providers aren’t necessarily the best fit for your specific needs. Their solutions often optimize for breadth rather than depth, which may not match your requirements. Smaller, specialized providers sometimes offer better capabilities for particular therapeutic areas or use cases at lower cost. Evaluating providers on the dimensions that matter for your applications, not on brand recognition, leads to better outcomes.
Underestimating the Analytical Lift Required
Access to data doesn’t automatically generate insights. Many companies license comprehensive databases only to realize they lack the internal expertise to analyze them effectively. Understanding your team’s capabilities honestly—and planning for either capability development or external analytical support—prevents data investments that sit unused.
Failing to Align Stakeholders on Use Cases
When commercial, medical affairs, and market access teams have different priorities for claims data, investments often satisfy no one fully. Aligning stakeholders on priority use cases before selecting providers ensures the chosen solution addresses the applications that matter most across functions.
Ignoring Total Cost of Ownership
Data licensing fees represent only part of total cost. Analytical services, internal resources for project management and interpretation, technology infrastructure for data integration, and ongoing maintenance add substantially to initial quotes. Understanding total cost of ownership prevents budget surprises and enables accurate ROI calculations.
The Strategic Value of Expert Navigation
The real-world evidence landscape continues growing more complex. New data sources emerge, analytical capabilities advance, privacy regulations evolve, and payer evidence requirements shift. Navigating this environment effectively requires staying current on developments most companies can’t justify monitoring internally.
This is where advisory expertise provides lasting value. Rather than evaluating claims data options every few years when new needs arise, partnering with advisors who maintain current landscape knowledge ensures you’re always aware of the best available options for emerging requirements.
Expert guidance accelerates decision-making (weeks instead of months), reduces costly missteps (avoiding providers that oversell capabilities), optimizes investment efficiency (matching spend to actual needs), and builds internal capabilities through knowledge transfer during engagements.
Most fundamentally, expert advisors align your claims data strategy with your business objectives rather than allowing vendor capabilities to drive use cases. The question isn’t “what can this data do?” but rather “what do we need to achieve, and which data capabilities enable that most effectively?”
Taking Action: Your Next Steps
If you’re ready to explore how claims data can transform your MedTech market access strategy, the path forward involves several concrete steps:
First, clarify your priority use cases and evidence gaps. What questions do you need answered that clinical trial data alone cannot address? Which market access challenges would benefit most from real-world intelligence? This clarity focuses subsequent evaluation on what actually matters.
Second, assess your internal capabilities honestly. Do you have the analytical expertise to work with claims data effectively? Would self-service tools sit unused, or do you have teams ready to leverage them? Understanding your capability baseline shapes the right engagement model.
Third, understand that the landscape is more complex than it appears. The claims data market includes dozens of providers with subtle but meaningful differences in coverage, capabilities, and cost models. What appears straightforward from the outside involves numerous trade-offs that require expertise to navigate effectively.
Most importantly, recognize that the gap between understanding what claims data can do theoretically and identifying which specific providers and approaches will deliver value for your organization is substantial. This is where expert guidance becomes critical—not just to avoid mistakes, but to accelerate your path to actionable intelligence that drives better decisions.
The MedTech companies succeeding with real-world evidence aren’t necessarily those with the biggest data budgets. They’re the ones who approached claims data strategically, aligned their investments with business priorities, and leveraged expert guidance to navigate a complex landscape efficiently.
Your competitors are already on this journey. The question is whether you’ll navigate it efficiently with expert guidance, or learn through expensive trial and error.
Ready to Explore Strategic Approaches to Real-World Intelligence?
Understanding what types of claims data exist and what questions they can answer is the first step. The second step—matching your requirements to the right combination of data sources, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the MedTech industry and the evolving real-world evidence ecosystem.
Contact MEDDDICAL today to discuss your specific data requirements and explore how expert advisory can help you navigate the complex claims data landscape, avoid costly missteps, and accelerate your path to actionable market access intelligence.
Sources & References
- U.S. Food and Drug Administration. (2023). Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices
- National Institute for Health and Care Excellence (NICE). (2022). NICE Real-World Evidence Framework. https://www.nice.org.uk/corporate/ecd9
- U.S. Food and Drug Administration. (2025). Real-World Evidence Program Overview. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- European Medicines Agency. (2024). Vision and Initiatives on Real-World Evidence in EU Medicines Regulation. https://www.ema.europa.eu/en/news/vision-use-real-world-evidence-eu-medicines-regulation
- Chen, R.J., Wang, J.J., Williamson, D.F.K., et al. (2023). Synthetic Data in Healthcare: A Comprehensive Review. Journal of Medical Internet Research. https://pmc.ncbi.nlm.nih.gov/articles/PMC9931305/